Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016

  • ID: 3775398
  • Drug Pipelines
  • 47 pages
  • Global Markets Direct
1 of 6
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016

Summary

‘Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016’, provides in depth analysis on Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted pipeline therapeutics.

The report provides comprehensive information on the Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)
- The report reviews Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Overview

Therapeutics Development

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Stage of Development

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Therapy Area

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Indication

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Companies

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Companies Involved in Therapeutics Development

Hadasit Medical Research Services & Development Ltd

VM Discovery, Inc.

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Drug Profiles

Bryostatin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DHACP-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-1201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Dormant Projects

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Discontinued Products

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Featured News & Press Releases

Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model

Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer’s Disease

Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer’s Disease

Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer’s Disease

Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference

Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease

Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual "Michael, Marcia & Christa Parseghian Scientific Conference" for Niemann-Pick Type C

Apr 16, 2015: Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies

Apr 09, 2015: Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome

Apr 06, 2015: Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease

Mar 30, 2015: Severe Alzheimer's Patient Responds to Bryostatin Treatment

Mar 17, 2015: Neurotrope Announces Positive Final Results from Its Phase 2a Safety Study for the Treatment of Alzheimer’s Disease

Feb 24, 2015: Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer's Disease

Nov 20, 2014: Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease

Aug 18, 2014: Neurotrope’s Approach to Treating Alzheimer’s Disease Through Its Product Bryostatin-1, an Activator of Protein Kinase C Epsilon (PKCe), Supported by Blanchette Rockefeller Neurosciences Institute (BRNI) Publication, Identifying PKCe as a Biomarker of Alzheimer’s

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016

Pipeline by VM Discovery, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.Our latest report Protein Kinase C Epsilon Type – Pipeline Review, H1 2016, outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 6 and 1 respectively.

Furthermore, this report also reviews key players involved in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Hadasit Medical Research Services & Development Ltd
VM Discovery, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll